Relay Therapeutics (RLAY) Retained Earnings (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Retained Earnings of -$2.1 billion for Q1 2026, down 5526415.79% year-over-year from N/an in Q1 2025, and down 181.37% quarter-over-quarter from $2.6 billion in Q4 2025.
Relay Therapeutics (RLAY) Retained Earnings (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Retained Earnings for 8 consecutive years, with -$2.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 5526415.79% year-over-year to -$2.1 billion; the TTM figure through Mar 2026 stood at -$2.1 billion (down 5526415.79% YoY), while the FY2025 annual figure was $2.6 billion, up 248.48% from the prior year.
- Retained Earnings retreated to -$2.1 billion in Q1 2026 per RLAY's latest filing, from $2.6 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $2.6 billion in Q4 2025 and bottomed at -$2.1 billion in Q1 2026.
- Historically, Retained Earnings has averaged $124.1 million across 5 years, with a median of -$9.2 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings jumped 185681.43% — and 2026, when it slumped 5526415.79%.
- Relay Therapeutics' Retained Earnings stood at $2.0 billion in 2022, then plunged by 100.01% to -$196000.0 in 2023, then plunged by 886782.65% to -$1.7 billion in 2024, then surged by 248.48% to $2.6 billion in 2025, then sank by 181.37% to -$2.1 billion in 2026.
- Business Quant data shows RLAY's Retained Earnings at -$2.1 billion in Q1 2026, $2.6 billion in Q4 2025, and -$2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 3.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.06 Bn |
| Mar 31, 2026 | -2.10 Bn |
| Dec 31, 2025 | 2.58 Bn |
| Sep 30, 2025 | -2.00 Bn |
| Jun 30, 2025 | -1.90 Bn |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | -1.74 Bn |
| Sep 30, 2024 | -1.70 Bn |
| Jun 30, 2024 | 2.26 Bn |
| Mar 31, 2024 | -1.48 Bn |
| Dec 31, 2023 | -196,000.00 |
| Sep 30, 2023 | 2.10 Bn |
| Jun 30, 2023 | 2.07 Bn |
| Mar 31, 2023 | 2.04 Bn |
| Dec 31, 2022 | 2.02 Bn |
| Sep 30, 2022 | -13.39 Mn |
| Jun 30, 2022 | -11.91 Mn |
| Mar 31, 2022 | -9.22 Mn |
| Dec 31, 2021 | -1.09 Mn |
| Sep 30, 2021 | 10,000.00 |